Back to top
October 7, 2016
FDA Approves Lundbeck's New Drug
Treatments

The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (≤7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.

Read the press release

Related News

February 20, 2018
News from Abroad: Xenon Pharmaceuticals Advances Second...

Xenon Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901.

February 19, 2018
Press Release: Final data from long-term study of CombiGene...

Final data from CombiGene’s preclinical proof-of-concept-study show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects.

February 16, 2018
FDA Eases Approval Path for Pediatric Epilepsy Drugs

A batch of new FDA guidance documents for neurology drugs support Commissioner Scott Gottlieb's oft-stated goal to offer manufacturers more...